AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment.

P. Kivisakk,T. Sweeney,B. C. Carlyle,B. A. Trombetta,K. LaCasse,L. El-Mufti,I. Tuncali,L. B. Chibnik,S. Das,C. R. Scherzer,K. A. Johnson,B. C. Dickerson,T. Gomez-Isla,D. Blacker,D. H. Oakley,M. P. Frosch,B. T. Hyman,A. Aghvanyan,P. Bathala,C. Campbell,G. Sigal,M. Stengelin,S. E. Arnold

Frontiers in neurology（2023）

引用 5|浏览36
暂无评分
摘要
These new ultrasensitive ECL plasma assays for pTau181, tTau, NfL, and GFAP demonstrated diagnostic utility for detection of AD. Moreover, the absolute baseline plasma levels of pTau181 and GFAP reflect cognitive decline over the next 4 years, providing prognostic information that may have utility in both clinical practice and clinical trial populations.
更多
查看译文
关键词
Alzheimer's disease,biomarker,glial fibrillary acidic protein (GFAP),mild cognitive impairment,neurofilament light (NfL),pTau181,plasma,total Tau (tTau)
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要